La vendita allo scoperto per Cyanotech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cyanotech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cyanotech (OTC:CYAN) Azioni, Report sulle vendite allo scoperto

Cyanotech

Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The company's products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health. It derives maximum revenue from the Packaged product and geographically from the United States.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

CYAN

NANX

RRGB

Scopri le 4 penny stock sotto $5 che stanno attirando l&#39;attenzione degli insider e valutane il potenziale di crescita.

4 penny stock sotto $5 che gli insider stanno acquistando

Scopri le 3 penny stock sotto $5 che stanno attirando l&#39;interesse degli insider per investimenti significativi.

Gli insider puntano su queste 3 penny stock sotto $5

VANI

Le recenti transazioni degli insider su Cyanotech, RENN Fund e Vivani Medical indicano fiducia nel mercato delle penny stock.

Penny stock: gli insider muovono il mercato con acquisti strategici

Cyanotech Corp

Cyan AG

The Dow Jones index closed higher by more than 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $0.80. To acquire these shares, it cost around $8,000.</li>
<li>What's Happening: On Aug. 7, Cyanotech announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">MSP Recovery</h3>
<ul>
<li>The Trade: MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) CEO John Hasan Ruiz <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 shares</a> at an average price of $0.25. To acquire these shares, it cost around $25,020.</li>
<li>What's Happening: On Aug. 19, MSP Recovery revealed a $3.1 million antitrust lawsuit settlement.</li>
<li>What MSP Recovery Does: MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services.</li>
</ul>
<h3 class="wp-block-heading">Eos Energy Enterprises</h3>
<ul>
<li>The Trade: Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) Director Alexander Dimitrief <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 3,000 shares</a> at an average price of $1.90. The insider spent around $5,685 to buy those shares.</li>
<li>What's Happening: On Aug. 6, Eos Energy Enterprises reported worse-than-expected second-quarter financial results.</li>
<li>What Eos Energy Enterprises Does: Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial &amp; industrial (C&amp;I) applications.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40439468/top-3-industrials-stocks-that-may-rocket-higher-this-month">Top 3 Industrials Stocks That May Rocket Higher This Month</a></li>
</ul>

Short Ideas

Pre-Market Outlook

EOSE

LIFW

Eos Energy Enterprises And 2 Other Stocks Under $2 Insiders Are Buying

Butterfly Network And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed higher by over 50 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Standard BioTools</h3>
<ul>
<li>The Trade: Standard BioTools Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) Director Casdin Private Growth Equity Fund, L.P. <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,069,562 shares </a> at an average price of $1.61. To acquire these shares, it cost around $1.72 million.</li>
<li>What's Happening: On July 31, Standard BioTools reported worse-than-expected quarterly financial results and cut FY24 revenue guidance below estimates..</li>
<li>What Standard BioTools Does: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at</a> an average price of $0.73. To acquire these shares, it cost around $7,250.</li>
<li>What's Happening: On Aug. 7, Cyanotech announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">PHX Minerals</h3>
<ul>
<li>The Trade: PHX Minerals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) SVP – CFO Raphael D&#8217;Amico acquired a total of 3,000 shares at an average price of $3.30. The insider spent around $9,898 to buy those shares.</li>
<li>What's Happening: On Aug. 12, PHX Minerals reported better-than-expected third-quarter financial results.</li>
<li>What PHX Minerals Does: PHX Minerals Inc is an oil and natural gas mineral company that has employed a plan to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40306547/dow-settles-higher-but-records-weekly-loss-greed-index-remains-in-extreme-fear-zone">Dow Settles Higher But Records Weekly Loss: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

$1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

The Dow Jones index closed lower by around 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions </a>platform.
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $0.77. To acquire these shares, it cost around $7,700.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">RENN Fund</h3>
<ul>
<li>The Trade: RENN Fund, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCG#NYSE">RCG</a>) President and CEO Murray Stahl <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,164 shares </a>at an average price of $1.79. To acquire these shares, it cost around $2,084.</li>
<li>What's Happening: RENN Fund shares gained around 7% over the past six months.</li>
<li>What RENN Fund Does: RENN Fund Inc is active in the financial services domain.</li>
</ul>
<h3 class="wp-block-heading">Vivani Medical</h3>
<ul>
<li>The Trade: Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) Chief Business Officer Donald Dwyer <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 9,000 shares</a> at an average price of $1.24. The insider spent around $11,120 to buy those shares. He also purchased 2,000 shares at $0.96.</li>
<li>What's Happening: Vivani Medical expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024.</li>
<li>What Vivani Medical Does: Vivani Medical Inc is a preclinical-stage biopharmaceutical company.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday">Amazon, Apple And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 220,083 shares at</a> an average price of $3.18. To acquire these shares, it cost around $699,165.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Anixa Biosciences</h3>
<ul>
<li>The Trade: Anixa Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) Director Arnold M Baskies <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares at</a> an average price of $3.09. To acquire these shares, it cost around $15,450.</li>
<li>What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.</li>
<li>What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.</li>
</ul>
<h3 class="wp-block-heading">Lifeloc Technologies</h3>
<ul>
<li>The Trade: Lifeloc Technologies, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LCTC#OTC">LCTC</a>) CFO Vern D Kornelsen <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 45,620 shares</a> at an average price of $3.80. The insider spent around $173,356 to buy those shares. </li>
<li>What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.</li>
<li>What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings">acquired a total of 10,000 shares </a>at an average price of $0.62. The insider spent around $6,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a></li>
</ul>

ABIO

ANIX

LCTC

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Retractable Technologies</h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVP#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 12,710 shares at</a> an average price of $1.13. To acquire these shares, it cost around $14,352.</li>
<li>What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales results.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3 class="wp-block-heading">Pineapple Financial</h3>
<ul>
<li>The Trade: Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) Director, CEO Shubha Dasgupta <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,000 shares at</a> an average price of $0.97. To acquire these shares, it cost around $1,938.</li>
<li>What's Happening: On July 16, Pineapple Financial posted a third-quarter loss of 12 cents per share.</li>
<li>What Pineapple Financial Does: Pineapple Financial Inc is a Canada-based mortgage technology and brokerage company that provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares</a> at an average price of $0.58. The insider spent around $5,800 to buy those shares. </li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39859847/netflix-to-rally-more-than-10-here-are-10-top-analyst-forecasts-for-friday">Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

PAPL

Pineapple Financial And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed higher by more than 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Alpha Teknova</h3>
<ul>
<li>The Trade: Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) 10% owner Telegraph Hill Partners Management Company, LLC <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 12,096,773 shares at</a> an average price of $1.24. To acquire these shares, it cost around $15 million. The company's Chief Financial Officer bought 40,000 shares, while CEO purchased 80,645 shares of the company.</li>
<li>What's Happening: On July 12, Teknova announced a $15.4 million private placement.</li>
<li>What Alpha Teknova Does: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at</a> an average price of $0.54. To acquire these shares, it cost around $5,400.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Blend Labs</h3>
<ul>
<li>The Trade: Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) Head of Finance and Admin. Amir Jafari <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 6,666 shares</a> at an average price of $2.54. The insider spent around $ $16,940 to buy those shares. </li>
<li>What's Happening: On May 8, Blend Labs posted upbeat quarterly results.</li>
<li>What Blend Labs Does: Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39791820/top-4-risk-off-stocks-youll-regret-missing-in-july">Top 4 Risk Off Stocks You&#8217;ll Regret Missing In July</a></li>
</ul>

BLND

TKNO

Over $15M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 408,777 shares at</a> an average price of $3.49. To acquire these shares, it cost around $1.4 million.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) President and CEO Jon Stenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,580 shares at</a> an average price of $2.59. To acquire these shares, it cost around $11,862.</li>
<li>What's Happening: On July 1, Citizens President Jon Stenberg was appointed Chief Executive Officer.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3 class="wp-block-heading">Willamette Valley Vineyards</h3>
<ul>
<li>The Trade: Willamette Valley Vineyards, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) CEO James W Bernau <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,978 shares</a> at an average price of $3.92. The insider spent around $11,682 to buy those shares. </li>
<li>What's Happening: On May 13, the company said sales revenue for the three months ended March 31, 2024 and 2023 was $8,803,080 and $8,308,940, respectively.</li>
<li>What Willamette Valley Vineyards Does: Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis a<a href="https://www.benzinga.com/quote/aei/analyst-ratings">cquired a total of 10,000 shares</a> at an average price of $0.42. The insider spent around $4,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Douglas Elliman</h3>
<ul>
<li>The Trade: Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) Director Mark Zeitchick <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 40,000 shares</a> at an average price of $1.18. The insider spent $47,196 to buy those shares.</li>
<li>What's Happening: On July 2, Douglas Elliman announced that it secured a $50 million growth investment from Kennedy Lewis Investment Management.</li>
<li>What Douglas Elliman Does: Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39748049/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings</a></li>
</ul>

DOUG

WVVI

Citizens And 4 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Expensify</h3>
<ul>
<li>The Trade: Expensify, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) 10% owner SF Roofdeck GP LLC <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 123,217 shares</a> at an average price of $1.45. To acquire these shares, it cost around $178,665.</li>
<li>What's Happening: On June 14, JMP Securities analyst Joe Goodwin reiterated Expensify with a Market Perform.</li>
<li>What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at</a> an average price of $0.36. To acquire these shares, it cost around $3,550.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Douglas Elliman</h3>
<ul>
<li>The Trade: Douglas Elliman Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) Director, Chairman, President &amp; CEO Howard M Lorber <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 shares</a> at an average price of $1.15. The insider spent around $114,563 to buy those shares. The company's Director Mark Zeitchick also bought 112,750 shares of the company.</li>
<li>What's Happening: On July 2, Douglas Elliman announced that it secured a $50 million growth investment from Kennedy Lewis Investment Management.</li>
<li>What Douglas Elliman Does: Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39708358/wall-streets-most-accurate-analysts-weigh-in-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

EXFY

Expensify And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Brightcove </h3>
<ul>
<li>The Trade: Brightcove Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcov#NASDAQ">BCOV</a>) 10% owner Jonathan Brolin <a href="https://www.benzinga.com/quote/BCOV/analyst-ratings"> acquired a total of 41,747 shares </a> an average price of $1.86. To acquire these shares, it cost around $77,667. The company&rsquo;s CEO also bought 25,000 shares of the company.</li>
<li>What&rsquo;s Happening: On Feb. 22, Brightcove reported fourth-quarter financial results and issued FY24 guidance below estimates..</li>
<li>What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.</li>
</ul>
<h3>Lumen Technologies</h3>
<ul>
<li>The Trade: Lumen Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lumn#NYSE">LUMN</a>) Director T Michael Glenn <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 50,000 shares at </a> at an average price of $1.47. To acquire these shares, it cost around $73,300.</li>
<li>What&rsquo;s Happening: On Feb. 6, Lumen Technologies reported better-than-expected fourth-quarter financial results.</li>
<li>What Lumen Technologies Does: With 450,000 route miles of fiber, Lumen Technologies is one of the United States&#39; largest telecommunications carriers serving global enterprises.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37327879/macys-lowes-and-3-stocks-to-watch-heading-into-tuesday"> Macy&#39;s, Lowe&#39;s And 3 Stocks To Watch Heading Into Tuesday </a>
<h3>Rezolute </h3>
<ul>
<li>The Trade: Rezolute, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rzlt#NASDAQ">RZLT</a>) Chief Medical Officer Brian Kenneth Roberts <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 8,000 shares </a> at an average price of $1.69. The insider spent around $13,540 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 13, Rezolute posted a narrower-than-expected second-quarter loss.</li>
<li>What Rezolute Does: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies.</li>
</ul>
<h3>Cyanotech </h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/cyan#OTC">CYAN</a>) VP, Operations Glenn Jensen <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings"> acquired a total of 16,835 shares </a> at an average price of $0.31. The insider spent around $5,222 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 8, Cyanotech posted a wider quarterly loss.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Small Cap

BCOV

LUMN

RZLT

Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying

<h3>Gainers</h3>
<ul>
<li>Bit Brother (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETS#NASDAQ">BETS</a>) shares rose 55.4% to $2.77 during Thursday's regular session. The market value of their outstanding shares is at $1.7 million. </li>
<li>Guardion Health Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHSI#NASDAQ">GHSI</a>) shares increased by 13.94% to $8.5. The market value of their outstanding shares is at $10.8 million. </li>
<li>China Jo-Jo Drugstores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJJD#NASDAQ">CJJD</a>) shares moved upwards by 12.66% to $0.2. The market value of their outstanding shares is at $6.7 million. </li>
<li>Maison Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) stock rose 12.26% to $1.1. The company's market cap stands at $21.6 million. </li>
<li>Webuy Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) shares rose 12.2% to $0.5. The company's market cap stands at $26.2 million. </li>
<li>Chanson International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares rose 11.84% to $1.7. The company's market cap stands at $21.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) stock declined by 14.0% to $0.62 during Thursday's regular session. The market value of their outstanding shares is at $4.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) shares declined by 13.28% to $0.18. The market value of their outstanding shares is at $5.8 million. </li>
<li>DDC Enterprise (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DDC#AMEX">DDC</a>) stock declined by 11.01% to $1.86. The company's market cap stands at $35.4 million. </li>
<li>MedAvail Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDVL#NASDAQ">MDVL</a>) shares declined by 10.48% to $2.82. The market value of their outstanding shares is at $4.5 million. </li>
<li>Steakholder Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKH#NASDAQ">STKH</a>) shares fell 10.44% to $0.64. The market value of their outstanding shares is at $17.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BETS

BTTR

CHSN

CJJD

GHSI

MDVL

Merrill Lynch & Strategic Return Notes for Select 10 Index

STKH

WBUY

11 Consumer Staples Stocks Moving In Thursday's Intraday Session

Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) reported quarterly losses of $(0.16) per share. This is a 60 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $5.58 million in sales this quarter. This is a 5.25 percent decrease over sales of $5.89 million the same period last year.

Earnings

Cyanotech Q3 EPS $(0.16) Down From $(0.10) YoY, Sales $5.58M Down From $5.89M YoY

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Cyanotech </h3>
<ul>
<li>The Trade: Cyanotech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyan#NASDAQ">CYAN</a>) Director Michael Davis <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings"> acquired a total of 400,000 shares </a> an average price of $1.00. To acquire these shares, it cost around $400,000.</li>
<li>What&rsquo;s Happening: On Nov. 8, Cyanotech posted a narrower loss for the second quarter.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3>BioAtla</h3>
<ul>
<li>The Trade: BioAtla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcab#NASDAQ">BCAB</a>) Director Lawrence Steinman <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $2.05. To acquire these shares, it cost around $41,048.</li>
<li>What&rsquo;s Happening: BioAtla, last month, said net loss for the third quarter was $33.3 million, versus a year-ago net loss of $25.8 million.</li>
<li>What BioAtla Does: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36300408/top-5-industrials-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 5 Industrials Stocks Which Could Rescue Your Portfolio This Quarter </a>
<h3>Beyond Air </h3>
<ul>
<li>The Trade: Beyond Air, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xair#NASDAQ">XAIR</a>) Director Robert Carey <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,200,000 shares </a> at an average price of $1.64. The insider spent around $1.96 million to buy those shares. The company&rsquo;s CEO and Chairman of the Board also bought 77,775 shares of the company.</li>
<li>What&rsquo;s Happening: On Nov. 13, Beyond Air posted downbeat quarterly results.</li>
<li>What Beyond Air Does: Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.</li>
</ul>
<h3>Cardiff Oncology </h3>
<ul>
<li>The Trade: Cardiff Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>) Director Gary Pace <a href="https://www.benzinga.com/quote/DFCO/analyst-ratings"> acquired a total of 30,000 shares </a> at an average price of $1.37. The insider spent around $41,100 to buy those shares.</li>
<li>What&rsquo;s Happening: On Nov. 2, Cardiff Oncology posted upbeat quarterly results.</li>
<li>What Cardiff Oncology Does: Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

BCAB

CRDF

XAIR

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>FTC Solar </h3>
<ul>
<li>The Trade: FTC Solar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftci#NASDAQ">FTCI</a>) Director Ahmad Chatila <a href="https://www.benzinga.com/quote/FTCI/analyst-ratings"> acquired a total of 14,550 shares </a> an average price of $0.68. To acquire these shares, it cost around $9,894.</li>
<li>What&rsquo;s Happening: On Nov. 8, FTC Solar reported mixed third-quarter financial results and issued guidance.</li>
<li>What FTC Solar Does: FTC Solar Inc is a global provider of advanced solar tracker systems, supported by proprietary software and value-added engineering services.</li>
</ul>
<h3>Retractable Technologies</h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 1,626 shares </a> at an average price of $1.15. To acquire these shares, it cost around $1,865.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/23/12/36068219/top-4-financial-stocks-that-may-fall-off-a-cliff-in-q4"> Top 4 Financial Stocks That May Fall Off A Cliff In Q4</a><a href="https://www.benzinga.com/news/earnings/23/12/36063278/saic-hawaiian-holdings-and-3-stocks-to-watch-heading-into-monday"> </a>
<h3>Cyanotech </h3>
<ul>
<li>The Trade: Cyanotech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyan#NASDAQ">CYAN</a>) Director Michael Davis <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 39,455 shares </a> at an average price of $0.90. The insider spent around $35,510 to buy those shares.</li>
<li>What&rsquo;s Happening: On Nov. 8, Cyanotech posted a narrower loss for the second quarter.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3>Jones Soda </h3>
<ul>
<li>The Trade: Jones Soda Co. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/jsda#OTC">JSDA</a>) Director Gregg Reichman <a href="https://www.benzinga.com/quote/JSDA/analyst-ratings"> acquired a total of 175,200 shares </a> at an average price of $0.15. The insider spent around $26,277 to buy those shares.</li>
<li>What&rsquo;s Happening: On Nov. 9, Jones Soda posted a narrower quarterly loss.</li>
<li>What Jones Soda Does: Jones Soda Co develops, produces, markets and distributes premium beverages which the company sells and distributes in the United States and Canada through its network of independent distributors and directly to its national and regional retail accounts.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

FTCI

JSDA

FTC Solar And 3 Other Stocks Under $2 Insiders Are Buying

Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $6.37 million in sales this quarter. This is a 23.05 percent increase over sales of $5.18 million the same period last year.

Cyanotech Q2 EPS $(0.13) Up From $(0.15) YoY, Sales $6.37M Up From $5.18M YoY

<h3>Gainers</h3>
<ul>
<li>Meiwu Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) stock moved upwards by 45.1% to $0.14 during Thursday's regular session. As of 13:31 EST, Meiwu Technology Co's stock is trading at a volume of 108.5 million, which is 23173.3% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million. </li>
<li>Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) stock moved upwards by 24.93% to $0.2. Trading volume for Better Choice Co's stock is 53.7 million as of 13:31 EST. This is 5499.9% of its average full-day volume over the last 100 days. The company's market cap stands at $6.4 million. </li>
<li>Planet Green Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLAG#AMEX">PLAG</a>) shares moved upwards by 12.69% to $0.74. Trading volume for this security as of 13:31 EST is 77.3K, which is 27.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $53.6 million. </li>
<li>Davis Commodities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) shares moved upwards by 12.45% to $3.43. Trading volume for this security as of 13:31 EST is 233.0K, which is 9.7% of its average full-day volume over the last 100 days. The company's market cap stands at $83.4 million. </li>
<li>Splash Beverage Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#AMEX">SBEV</a>) stock increased by 10.65% to $0.68. The current volume of 128.6K shares is 50.9% of Splash Beverage Group's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $28.9 million. </li>
<li>Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) stock increased by 9.54% to $99.13. Lamb Weston Hldgs's stock is trading at a volume of 4.6 million shares as of 13:31 EST. This is 290.0% of its average full-day volume over the last 100 days. The company's market cap stands at $14.4 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zivo Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIVO#NASDAQ">ZIVO</a>) shares declined by 22.5% to $1.0 during Thursday's regular session. The current volume of 73.4K shares is 535.7% of Zivo Bioscience's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $10.4 million. </li>
<li>Alkaline Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTER#NASDAQ">WTER</a>) shares fell 13.12% to $0.27. Trading volume for Alkaline Water Co's stock is 343.9K as of 13:31 EST. This is 172.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.9 million. </li>
<li>Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) shares decreased by 12.41% to $1.09. As of 13:31 EST, this security is trading at a volume of 518.3K shares, making up 69.0% of its average full-day volume over the last 100 days. The company's market cap stands at $35.5 million. </li>
<li>Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) stock decreased by 10.8% to $0.78. The market value of their outstanding shares is at $5.0 million. </li>
<li>Missfresh (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MF#NASDAQ">MF</a>) shares decreased by 8.88% to $0.82. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTCK

PLAG

SBEV

SHOT

WTER

ZIVO

Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) reported quarterly losses of $(0.22) per share. This is a 175 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $5.15 million in sales this quarter. This is a 23.38 percent decrease over sales of $6.72 million the same period last year.

Cyanotech Q1 EPS $(0.22) Down From $(0.08) YoY, Sales $5.15M Down From $6.72M YoY

Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) reported quarterly losses of $(0.23) per share. This is a 675 percent decrease over earnings of $0.04 per share from the same period last year. The company reported $5.39 million in sales this quarter. This is a 33.67 percent decrease over sales of $8.13 million the same period last year.

Cyanotech Q4 EPS $(0.23) Down From $0.04 YoY, Sales $5.39M Down From $8.13M YoY

On June 15, Cyanotech Corp Received Letter From Nasdaq Notifying Co It Has Regained Compliance With Listing Rule 5550(A)(2)

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30.</a>
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Better Choice Company Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bttr#NYSE">BTTR</a>)</h3>
<ul>
<li>Better Choice said Sharla A. Cook has resigned from her role as CFO, Secretary and Treasurer of the company, effective April 3, 2023. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/BTTR">52-week low of $0.3247 </a>.</li>
<li>RSI Value: 27.42</li>
<li>BTTR Price Action: Shares of Better Choice Company dropped 7.9% to close at $0.35 on Thursday.</li>
</ul>
<h3>Rite Aid Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rad#NYSE">RAD</a>)</h3>
<ul>
<li>Rite Aid plans to dispense abortion pill mifepristone in a limited number of its pharmacies and will serve customers in person or through mail delivery. The company&rsquo;s <a href="https://www.benzinga.com/quote/RAD"> stock has a 52-week low </a> of $2.1850.</li>
<li>RSI Value: 28.45</li>
<li>RAD Price Action: Shares of Rite Aid dropped 6.3% to close at $2.22 on Thursday.</li>
</ul>
<h3>Vintage Wine Estates, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vwe#NASDAQ">VWE</a>)</h3>
<ul>
<li>Vintage Wine Estates announced the sale of Tenma Vineyard for $11 million in cash. The company&rsquo;s stock has a 52-week <a href="https://www.benzinga.com/quote/VWE"> low of $0.97.</a></li>
<li>RSI Value: 23.60</li>
<li>VWE Price Action: Shares of Vintage Wine Estates fell 5.3% to close at $0.9849 on Thursday.</li>
</ul>
<h3>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>)</h3>
<ul>
<li>Veru filed for <a href="https://www.benzinga.com/quote/VERU"> mixed shelf </a> of up to $200 million. The company&rsquo;s 52-week low is $1.28.</li>
<li>RSI Value: 18.13</li>
<li>VERU Price Action: Shares of Veru dropped 6.8% to close at $1.31 on Thursday.</li>
</ul>
<h3>Cyanotech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyan#NASDAQ">CYAN</a>)</h3>
<ul>
<li>Cyanotech posted a Q3 loss of $0.10 per share. Cyanotech&rsquo;s President and Chief Executive Officer, Matthew K. Custer, said, &quot;Sales in the third quarter improved by $712,000, or 14%, compared to the second quarter, as we saw modest improvement in consumer movement on both finished goods and bulk sales. However, both of our online finished good sales and our international bulk sales are still not performing to historical levels.&quot; The company <a href="https://www.benzinga.com/quote/CYAN"> has a 52-week low </a> of $0.8751.</li>
<li>RSI Value: 29.76</li>
<li>CYAN Price Action: Shares of Cyanotech fell 3.3% to close at $0.8801 on Thursday.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/23/03/31487311/oxford-industries-express-and-3-stocks-to-watch-heading-into-friday"> Oxford Industries, Express And 3 Stocks To Watch Heading Into Friday </a>

VERU

Vintage Wine Estates, Inc. - Common Stock

Top 5 Defensive Stocks That Are Set To Fly

Cyanotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#NASDAQ">CYAN</a>) reported quarterly losses of $(0.10) per share. This is a 266.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $5.89 million in sales this quarter. This is a 37.72 percent decrease over sales of $9.46 million the same period last year.

Cyanotech Q3 EPS $(0.10) Down From $0.06 YoY, Sales $5.89M Down From $9.46M YoY

Cyanotech GAAP EPS of -$0.13, revenue of $6.37M

Cyanotech GAAP EPS of -$0.16, revenue of $5.58M

Cyanotech Corporation (CYAN) Q3 2024 Earnings Call Transcript

Cyanotech Corp. (CYAN) has released an update. Cyanotech Corporation is facing delisting from Nasdaq after its stock price remained below the $1.00...

Cyanotech Corp. Faces Nasdaq Delisting Over Stock Price

Cyanotech GAAP EPS of -$0.81, revenue of $23.07M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyanotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyan-stock-quote/">CYAN</a>) just reported results for the fourth quarter of 2024.<ul><li>Cyanotech reported earnings per share of -30 cents.</li><li>The company reported revenue of $5.97 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/cyan-stock-earnings-cyanotech-for-q4-of-2024/">CYAN Stock Earnings: Cyanotech Reported Results for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYAN Stock Earnings: Cyanotech Reported Results for Q4 2024

Cyanotech GAAP EPS of -$0.17, revenue of $5.89M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyanotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyan-stock-quote/">CYAN</a>) just reported results for the first quarter of 2025.<ul><li>Cyanotech reported earnings per share of -17 cents.</li><li>The company reported revenue of $5.90 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cyan-stock-earnings-cyanotech-for-q1-of-2025/">CYAN Stock Earnings: Cyanotech Reported Results for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYAN Stock Earnings: Cyanotech Reported Results for Q1 2025

The latest announcement is out from Cyanotech (CYAN). At the Company's 2024 Annual Meeting, stockholders elected four directors, endorsed a stock g...

Comments

Cyanotech

Vendite allo scoperto

Cyanotech (OTC:CYAN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO